New inhibitor of complement activation second pathway, the disclosure of the new anti-factor B antibody in particular. In addition, the use of the inhibitor in order to perform prevention or mitigation of airway inflammation and / or airway hyperresponsiveness by selectively inhibiting complement activation second route, to handle the diseases related to the symptoms by it disclosure. In addition, disclosure of the use of the inhibitor to prevent or alleviate the symptoms and other diseases involving ischemia-reperfusion injury by inhibiting the activation of complement alternative pathway.補体活性化第二経路の新規抑制剤、特に新規抗B因子抗体の開示。また、補体活性化第二経路を選択的に抑制して気道過敏性および/または気道炎症の緩和または予防を行い、それによって前記症状が関与する疾患を処理するための前記抑制剤の使用の開示。また、補体活性化第二経路を抑制して虚血再かん流傷害を含む他の疾患および症状を緩和または予防するための前記抑制剤の使用の開示。
